Health & Fitness
Health and Fitness
Health and Fitness
Tue, June 22, 2010
Mon, June 21, 2010 
INDIANAPOLIS--([ BUSINESS WIRE ])--Positron Corporation (OTCBB:POSC), a leader as a molecular imaging and solutions company specializing in the field of Nuclear Cardiology, announces the sales of four Attriusa" PET scanners to prominent cardiology practices and orders six Attriusa" PET scanners from its joint venture, Neusoft Positron Medical Systems for immediate delivery.
As a result of the Centers for Medicare & Medicaid Services (CMS) 2010 Medicare Physician Fee Schedule whereby reimbursement for cardiac PET increased and reimbursement for SPECT decreased there has been a significant increase in demand for cardiac PET imaging. When combining the economic and medical imaging advantages of cardiac PET compounded with the continued shortage of Molybdenum, the parent radioisotope used in SPECT imaging, this increase in the demand for cardiac PET is a trend that is expected to continue.
Positrona™s cardiac optimized dedicated PET scanner the Attriusa" is the right choice at the right time for cardiovascular practices. With recent sales, Positron has met its six month projections and predicts greater demand moving forward. Based on Positrona™s sales pipeline and in preparation of meeting the next six month projections, the Company has place a purchase order for six systems for their earliest delivery. Positrona™s organic growth targets sales of 17 PET systems for 2010, 50 PET systems for 2011 and 125 PET systems for 2012 and fully expects to meet these goals.
Patrick G. Rooney, Chief Executive Officer of Positron stated, aPositron has always been a leader in cardiac PET and we continue to make progress that further validates our position that PET is the future of nuclear cardiology. Positron is ideally positioned with the Attriusa" as the only dedicated cardiac PET offering available. This year has seen the emergence of cardiac PET and Positron. Our objective is to meet the strong demand and be the full solutions provider for cardiac PET adopters. Positron projects an increase in sales every quarter for the foreseeable future and is prepared to deliver. Positrona™s corporate focus is aggressive growth while staying on track to deliver positive earnings within 18 months.a
About Positron: Positron is a molecular imaging company focused on Nuclear Cardiology. Positron utilizes its proprietary product line to provide unique solutions to the Nuclear Medicine community ranging from imaging to radiopharmaceutical distribution. Positron products include: the Attriusa", a PET imaging device; the Pulse®, a SPECT imaging device; the Nuclear Pharm-Assist®, an automated radiopharmaceutical distribution device; and the Tech-Assista", a radiopharmaceutical injection shield. More information about Positron is available at [ www.positron.com ].
Forward Looking Statements: Statements in this document contain certain forward-looking statements within the meaning of Section27A of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended. These statements are based on many assumptions and estimates and are not guarantees of future performance and may involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Positron Corporation to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Our actual results may differ materially from the results anticipated in these forward-looking statements due to a variety of factors, including, without limitation those set forth as "Risk Factors" in our filings with the Securities and Exchange Commission.
For further information please contact Positron Corporation at (317)576-0183.
